Treatment for Dermatologic Complications

Waitlist Available · 18+ · All Sexes · Harvey, IL

This study is evaluating whether a gel can help relieve pain and itching in people who develop an acne-like rash while undergoing treatment with cetuximab or another epidermal growth factor receptor inhibitor for cancer.

See full description

About the trial for Dermatologic Complications

Eligible Conditions
Dermatologic Complications · Unspecified Adult Solid Tumor, Protocol Specific

Treatment Groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.


This trial is for patients born any sex aged 18 and older. There are 7 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
No known history of hypersensitivity to amine-type local anesthetics or to other components of MPM Regenecare® wound gel
No other concurrent, serious skin disorders (i.e., scleroderma or psoriasis) that would interfere with assessment of EGFR inhibitor-induced rash
No other concurrent topical facial creams or lotion
Diagnosis of cancer
Starting treatment with cetuximab or other EGFR inhibitor (e.g., erlotinib hydrochloride) on another clinical trial
Not pregnant or nursing
See Disease Characteristics
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Up to 5 years
Screening: ~3 weeks
Treatment: Varies
Reporting: Up to 5 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Up to 5 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 1 primary outcome and 2 secondary outcomes in patients with Dermatologic Complications. Measurement will happen over the course of .

Tolerability of Regenecare® wound gel as assessed by NCI CTCAE v3.0
Efficacy of Regenecare® wound gel, in terms of alleviating pain and itching
Efficacy of Regenecare® wound gel, in terms of reducing severity, redness, and appearance of rash

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How does treatment work?

The findings of this study suggest that psychological therapy has an effect on psychological distress and that a large portion of participants can be managed on an individual basis.

Anonymous Patient Answer

How many people get dermatologic complications a year in the United States?

Approximately 60% of patients with inflammatory bowel disease develop skin lesions. These are associated with greater morbidity and resource utilization with potential for cost savings by improved healthcare utilization.

Anonymous Patient Answer

Can dermatologic complications be cured?

Despite the high cure success rate, severe skin problems can affect the overall QOL. Appropriate referral to an orthopedic surgeon is important to treat the majority of cases. Nevertheless, it is important to keep the expectation for cure high by proper adherence to treatment and adherence to wound care hygiene measures. Dermatologic complications can be highly significant and debilitating, even when the condition is cured. It must be stressed that complications are not necessarily cure.

Anonymous Patient Answer

What causes dermatologic complications?

Various dermatologic conditions are comorbid with psychiatric disorders. The main factors to keep in mind are the psychiatric disorders and their adverse effects on skin health. There are many possible reasons for dermatologic complications in psychiatric settings. A multidimensional assessment is always advisable.

Anonymous Patient Answer

What is dermatologic complications?

The increased severity of the psoriasiform eruptions with the use of PUVA was in line with the theoretical assumption that PUVA treatment enhances the expression of psoriasiform plaques through the direct stimulation of the immune system and of the epidermis.

Anonymous Patient Answer

What are the signs of dermatologic complications?

Some of the signs of dermatologic complications are erythema, blisters and oozing. The skin can become ulcerated and very hard (hardened) (atherma) or very pale or scaly or dry or red or very flaky (fragmented) with itching, pruritus, itching with scratching or skin oozing. Skin lesions may sometimes be telangiectatic-like with blood vessels around the skin (telangiectasias) or more generally with skin scars or skin atrophies.

Anonymous Patient Answer

What are common treatments for dermatologic complications?

While there is no consensus on what to do in cutaneous CD, almost half the patients reported some sort of treatment for skin involvement, most commonly topical steroids and antifungal preparations.

Anonymous Patient Answer

What is the average age someone gets dermatologic complications?

The mean time of the onset of new-onset dermatologic complications in this study was 6.9 months after the beginning of therapy. This is similar at our referral center and other referral centers nationwide. We have found that dermatologic complications are not the only reason to replace a medication but that patients who have had adequate skin toxicity monitoring should be continued on the previously initiated medication unless they experience a skin reaction. We found that approximately half of all patients experienced a skin reaction after discontinuing the medication, often to a rash. We recommend patients with skin toxicity should be asked to notify their provider if they acquire skin complications or a rash.

Anonymous Patient Answer

Does treatment improve quality of life for those with dermatologic complications?

Treatment does change patients' perceived quality of life. The changes that arise from treatment may alter clinical outcomes and therefore need to be considered when deciding whether a patient should undergo treatment.

Anonymous Patient Answer

How serious can dermatologic complications be?

In the past, this study has shown that the serious complications of skin/dermatologic complications can occur. Thus, we must use great caution when considering treatment plans to avoid serious complications and promote skin/dermatologic recovery. There are several ways of categorizing the possibility of skin/dermatological complications. I would like to summarize those different ways here and use them when discussing treatment options after amputation. 1. A: Skin/dermatologic complications can be classified as minor, moderate, and major complications. Obviously the possibility of skin/dermatologic complications is very different when you are considering any treatment, and thus this categorization does not have any clinical significance.

Anonymous Patient Answer

What does treatment usually treat?

Patient perceptions of treatment vary widely with different treatments. As a clinical trial evolves from clinical theory to clinical practice in the clinic, the number of treatments proposed by the researchers is increasing. Researchers should take patient perceptions of treatment into consideration to determine the best course of care, and treatment choices should be reflective of the patient's experiences.

Anonymous Patient Answer

Does dermatologic complications run in families?

In our study, we found that dermatologic complications in patients with inflammatory bowel disease (IBD) were most accurately predicted by siblings with IBD and were not substantially different from those in patients with familial autoimmune gastritis. We found no evidence that dermatologic complications were associated with a genetic factor.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Dermatologic Complications by sharing your contact details with the study coordinator.